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Objectives: Inflammatory markers such as high-sensitivity C-reactive protein (hsCRP) are associated with an increased risk of
cardiovascular events and with the severity of peripheral arterial disease. The effects of inflammation on the development of
vein graft disease remain speculative. We hypothesized that high levels of inflammatory markers would identify patients at
increased risk for adverse events (graft failure, major cardiovascular events) after lower extremity bypass surgery.
Methods: Patients (n  91) scheduled to undergo lower extremity bypass using autogenous vein were enrolled into a
prospective study at two institutions. Exclusion criteria included the presence ofmajor infection. A baseline plasma sample was
obtained on the morning of lower extremity bypass. Biomarkers for inflammation included hsCRP, fibrinogen, and serum
amyloid A (SAA). Values between patients with and without critical limb ischemia were compared. Proportions of events
among dichotomized populations (upper limit of normal of each laboratory assay) were compared by log-rank test.
Results: Of the patients undergoing lower extremity bypass, 69% were men, 53% were diabetic, 81% were smokers, and
their mean ankle-brachial index was 0.51 0.19. The indication for lower extremity bypass was critical limb ischemia in
55%. There were no perioperative deaths and two early graft occlusions. During a mean follow-up of 342 days (range,
36-694 days) there were four deaths, 27 graft-related events, and 10 other cardiovascular events. No relationships were
found between events and demographics, comorbidities, baseline ankle-brachial index, or statin use. High-sensitivity
CRP (P  .005), fibrinogen (P < .001), and SAA (P  .0001) levels were associated with critical limb ischemia at
presentation. Among patients with an elevated hsCRP (>5 mg/L) immediately before surgery, major postoperative
vascular events occurred in 60% (21/35), compared with a 32% (18/56) rate in those with a baseline CRP <5 mg/L
(P  .004, log-rank test). On multivariable analysis, only elevated hsCRP correlated with adverse graft-related or
cardiovascular events (P  .018).
Conclusions: The inflammatory biomarkers of hsCRP, fibrinogen, and SAA correlate with peripheral arterial disease
severity at presentation in patients undergoing lower extremity bypass. Patients with elevated hsCRP are at increased risk
for postoperative vascular events, most of which are related to the vein graft. These findings suggest a potential
relationship between inflammation and outcomes after lower extremity vein bypass surgery. (J Vasc Surg 2007;45:2-9.)Approximately 10 million individuals have peripheral ar-
tery disease (PAD) in the United States, with a prevalence that
approaches 10% in individuals aged 60 years.1 Among the
most severely affected, nearly 100,000 peripheral artery recon-
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2structionswill be performed annually. Patients with PADhave
coronary artery disease and cerebrovascular disease as comor-
bidities andhave amortality risk proportional to the severity of
PAD.2 Atherosclerosis is an inflammatory disease3 with highly
variable clinical progression. Hence, attention has turned to
the use of inflammatory markers such as high-sensitivity C-re-
active protein (hsCRP) for prognostic4-10 and potentially
therapy-guiding purposes.4,11-13
Vein bypass surgery can provide effective and durable
revascularization for patients with advanced PAD. How-
ever, vein graft failure occurs in 30% to 50% of patients
5 years,14,15 necessitating additional procedures and as-
sociated morbidity. Patient-specific risk factors remain
poorly defined. Experimental studies demonstrate a promi-
nent acute inflammatory response in the arterialized vein and
have suggested that modulation of inflammation might influ-
ence the subsequent development of vein graft hyperpla-
sia.16-19 Recent clinical observations, including reports of a
possible beneficial effect of 3-hydroxy-3-methylglutaryl co-
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lend further support to this concept. The role of inflamma-
tion in the incidence and progression of clinical vein graft
disease remains highly speculative, however.
Beyond traditional lipid-fraction-based cardiovascular
risk assessment, hsCRP has emerged as a predictive marker
for myocardial infarction,4,21-23 stroke,4 and PAD,24,25
in apparently healthy men and women, thus associating
chronic inflammation with these end points.26 Individuals
with PAD have higher levels of hsCRP,27,28 and hsCRP
also appears to be predictive of PAD progression as mea-
sured by both ankle-brachial index (ABI)29 and severity of
functional impairment.30,31 Among individuals with PAD,
hsCRP relates to both severity of disease on presentation
and future cardiovascular events,27,32-34 including myocar-
dial infarction in patients undergoing revascularization.34
Fibrinogen and serum amyloid A (SAA) are other cir-
culatingmarkers of inflammation in addition to hsCRP that
are associated with cardiovascular disease (including PAD)
and death.14,35-37 SAA is associated with the presence of
coronary artery disease as well as with the development of
cardiovascular complications in women presenting for cor-
onary angiography.37 Fibrinogen levels are higher in sub-
jects with PAD26,28 and are predictive of adverse cardiovas-
cular events in this population.35
We hypothesized that inflammation is directly related
to the development of vein graft disease as well as to the
global atherosclerosis risk within the PAD population re-
quiring surgical therapy. The overall goals of our investiga-
tion were to examine the relationships between circulating
markers of inflammation, clinical events, and patterns of
vein graft remodeling in patients undergoing infrainguinal
bypass surgery for advanced PAD.
METHODS
Study design and population. This prospective co-
hort study examined the relationship between inflamma-
tory markers and cardiovascular outcomes in patients un-
dergoing lower extremity bypass with autogenous vein
grafts. This study was undertaken at two Boston-area teach-
ing hospitals and was approved by their respective Institu-
tional Review Boards. Study enrollment began in February
2004 and was closed for this particular analysis in Decem-
ber 2005.
Patients were excluded if a nonautogenous conduit (in
whole or in part) was used in their infrainguinal reconstruc-
tion, if they were unlikely to fully comply with the follow-up
protocol (eg, long distance travel), or if they were unable to
provide informed consent. Patients were also excluded if
they had clinical evidence of infection including cellulitis,
osteomyelitis, or deep space infection of the foot, or if they
required operative débridement for sepsis control before
bypass grafting. Other exclusion criteria included the use of
immunosuppressive medications, concurrent systemic in-
fections (eg, pneumonia, genitourinary tract infections),
acute illness such as myocardial infarction or stroke, or any
major surgery 30 days. All participants in this study
provided written informed consent, and the protocol wasapproved by the Institutional Review Board of the Brigham
and Women’s Hospital (Boston, Mass).
Blood collection and assays for inflammatory
markers. Plasma and blood were collected on the morn-
ing of the subject’s index lower extremity bypass surgery by
direct femoral vein puncture after the patient was anesthe-
tized and before any surgical incision. Blood was collected
into ethylenediaminetetraacetic acid and citrate Vacutainer
tubes (BD Diagnostics, Franklin Lakes, NJ) and immedi-
ately iced. Tubes were spun at 3000 rpm for 20 minutes at
4°C in a refrigerated centrifuge. Baseline blood samples of
the participants were stored at –70°C until the time of
analysis. Assays for hsCRP, SAA, and fibrinogen were per-
formed in a core laboratory using validated, high-sensitivity
assays, as previously described.38 All marker assays were
performed as a single batch at the conclusion of the study.
Operative procedures and clinical follow-up. Patients
underwent autogenous lower extremity revascularization
using standard techniques under the direction of the at-
tending vascular surgeon, with either regional or general
anesthesia. Five patients were subsequently excluded from
the study because poor quality vein at the time of surgery
required the use of a nonautogenous graft.
Details of the operative procedure were recorded, in-
cluding the nature of the reconstruction, the need for
adjunctive procedures, and the results of completion imag-
ing studies. It is the standard practice of all participating
surgeons to perform duplex ultrasound or completion an-
giogram, or both, as an intraoperative completion study.
Any flow disturbances or intrinsic vein disease would be
identified at this time. Preoperative and postoperative med-
ical therapies, including the use of antithrombotics, were at
the discretion of the attending surgeon and were recorded.
All patients were monitored for postoperative complica-
tions during their initial hospitalization and at all subsequent
visits. All patients enrolled were followed up postoperatively
by the attending vascular surgeon and received duplex ultra-
sound imaging surveillance at 1, 3, 6, 9, and 12 months,
which is consistent with our standard practice. The duplex
ultrasound examination was performed in an accredited vas-
cular laboratory by a registered vascular technician.
After 12 months, the follow-up visits occurred every
6 months. All patients underwent a complete vascular
examination at these follow-up time points and were eval-
uated for clinical and graft-related events and changes in
their medication usage. In addition to the scheduled
follow-up visits, two research coordinators, and a clinical
research fellow (C. D. O.) monitored events through con-
tact with the patients, their primary care providers, and the
electronic medical record.
Definition of end points. Graft-related events included
any graft revision (patch angioplasty or interposition graft),
any percutaneous intervention to the bypass (balloon angio-
plasty), any graft occlusion (either salvaged or abandoned), or
amputation in the index leg. Because four patients were iden-
tified near the closing of the study to have high-grade stenosis
on graft surveillance (peak systolic velocity 300 cm/s or
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stenosis was included as a graft-related end point.
Contralateral limb events were any peripheral revascu-
larization of the limb contralateral to the index limb, in-
cluding percutaneous transluminal angioplasty/stent, open
endarterectomy, or open revascularization with a bypass
graft, as well as any major amputation.
Major cardiovascular events included stroke, myocardial
infarction, cardiac revascularization procedure, or death from
any cause. Myocardial infarction was documented by the
presence of new Q waves with or without changes in the ST
segments by standard 12-lead electrocardiograms and by spe-
cific enzyme elevations. All patientswithmyocardial infarction
were seen by the cardiovascular medical service and the event
was documented. A stroke was diagnosed by clinical evidence
of focal neurologic deficit lasting 24 hours and correlated
with an imaging modality such as computed tomography or
magnetic resonance imaging. All strokesweredocumentedby a
neurologic consultant. An attempt was made at each death to
determine thecause,but thiswasnotpossible in all circumstances
because of refusal to consent for postmortem examination.
The primary end point of this study was a composite
incidence of death, graft-related events, contralateral limb
events, or other major cardiovascular events as defined.
Statistical methods. Student’s t test or 2 was used to
evaluate differences in means and proportions between pa-
tients with events and those without. The distribution of all
inflammatory markers was non-Gaussian (rightward skewed)
and is presented as median and interquartile range. Plasma
levels of markers and bivariate relationships were analyzed by
the one-way nonparametric analysis of variance (Kruskal-Wal-
lis test) or the two-sample Wilcoxon rank sum (Mann-Whit-
ney) test, where appropriate. Inter-relations between individ-
ual inflammatory markers were determined by linear
regression of their natural log-transformations, as has been
previously described.38 Correlations between inflammatory
markers and collected parameters were evaluated with the
Spearmanmethod. The r value is reported for all linear regres-
sions. Multivariable logistic regression was used to rule out
covariation between the collected parameters.
For each inflammatory marker, subjects were dichoto-
mized (normal or elevated) according to the upper limits of
the core laboratory’s reference ranges of hsCRP5.0 mg/L,
SAA.97mg/dL, and fibrinogen400mg/dL. Univariate
analysis was performed to assess the independent contribution
of the risk factors to adverse cardiac and graft-related events.
All variables with P  .10 on univariate analysis were
placed into a multivariable Cox proportional hazard model.
The Kaplan-Meier method was used to compare the event-
free survival rate among subjects, and comparisons were
made with the log-rank test. For all event-rate analysis,
subjects not experiencing an adverse event were censored at
the conclusion of the study (December 31, 2005) as being
alive with a patent graft and not experiencing any event.
P values were two-tailed, and P  .05 is reported as
significant. Statistical analyses were performed on Inter-
cooled Stata 7.0 (StataCorp, College Station, Tex).RESULTS
Patient demographics and risk factors. Subject de-
mographics and risk factor profiles are presented in Table I.
Briefly, of the 91 patients enrolled, 63 were men (69.2%);
79 were white (86.8%), 7 were African American (7.7%),
and 5 were Hispanic (5.5%); 48 (53%) had diabetes melli-
tus, 44 (49.4%) had a known history of coronary artery
disease, 5 (5.5%) had end-stage renal disease, 74 (81.3%)
had hypertension, 73 (80%) were either current or former
smokers, and 65 (72%) were currently taking a HMG CoA
reductase inhibitor.
Surgical procedures. The indication for the revascu-
larization was critical limb ischemia, defined as rest pain or
tissue loss, in 50 subjects, claudication in 32, and repair of
a popliteal aneurysm in nine. Autogenous conduits in-
cluded a single segment of great saphenous vein (reversed
or nonreversed) in 72, spliced great saphenous or short
saphenous vein in 5, single-segment arm vein in 5, and
spliced arm vein in 9. Inflow sites included the common
femoral artery in 56, superficial femoral artery in 21, or
popliteal artery in 14. Distal anastomoses were performed
to the popliteal artery in 44, tibial in 27, or pedal vessels in
20. Early (30-day) graft failure occurred in two patients.
Markers of inflammation. Baseline levels of the in-
flammatory markers are summarized in Table II. Median
hsCRP was 3.2 mg/L (interquartile range, 1.4 to 15), SAA
was 0.91 mg/dL (interquartile range, 0.52 to 2.0), and
fibrinogen was 472 mg/dL (interquartile range, 396 to
569). Levels of all three inflammatory markers were higher
in the patients operated on for critical limb ischemia than
for non-critical limb ischemia: hsCRP, 6.84 vs 2.02 mg/L
(P  .001); SAA, 1.37 vs 0.74 mg/dL (P  .008); and
fibrinogen, 516.2 vs 434.4 mg/dL (P  .001) (Fig 1).
High-sensitivity CRP was positively correlated with fibrin-
ogen (r  0.68, P  .001) and SAA (r  0.75, P  .001).
On Spearman analysis (Table III), diabetes mellitus and
critical limb ischemia were significantly correlated with
hsCRP, SAA, and fibrinogen. The presence of end-stage
Table I. Characteristics of study population at baseline
Characteristic N (%)
Age (mean  SD) 63  11.5
Male sex 63 (69)
Race
White 79 (86.8)
African American 7 (7.7)
Hispanic 5 (5.5)
CAD 44 (49.4)
Diabetes mellitus 48 (52.8)
ESRD 5 (5.5)
Smoking history 73 (81.0)
Hypertension 74 (81.3)
Current statin use 65 (72.2)
CLI 50 (55.0)
CAD, Coronary artery disease; ESRD, end-stage renal disease; CLI, critical
limb ischemia.renal disease was correlated with hsCRP and SAA but not
and interquartile range.
All data are shown as median (interquartile range) except ABI (mean).
*Values are significant between ()/() subgroups (P  .01).
e
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cantly correlated with hsCRP.
We performed a forward-building stepwise logistic re-
gression to determine the factors that were independently
associated with levels of inflammatory markers. This in-
cluded age, gender, race, diabetes mellitus, statin use, hy-
pertension, smoking, hyperlipidemia, and the presence of
critical limb ischemia in the model. Of these factors, only
critical limb ischemia (P  .001), diabetes mellitus (P 
.003), and hypertension (P  .003) were significantly
associated with CRP.When these same variables were used,
diabetes mellitus (P  .004), critical limb ischemia (P 
.002), and end-stage renal disease (P  .014) were signif-
icantly associated with SAA, and diabetes mellitus (P 
.006), critical limb ischemia (P .001), and hypertension,
(P  .006) were significantly associated with fibrinogen.
Relationship between inflammatory markers and
adverse events. During a mean follow-up of 342 days
(range, 36 to 694; median, 320 days), 41 adverse events
occurred in this study. Two subjects hadmore than one event,
but for all time-to-event analysis, only the first one was con-
sidered. In the perioperative (30-day) period, there were no
) Fibrinogen (mg/dL) SAA (mg/dL)
472 (396-569) .91 (.52-2.0)
.3)* 516.2 (447.6-656.3)* 1.37 (.59-3.5)*
4)* 434.4 (361.3-500.2)* .74 (.37-1.1)*
)* 465.1 (404.1-639.6) .9 (.54-4.1)
* 473.6 (394.9-550.3) .9 (.52-1.5)
lower-extremity bypass;CLI, critical limb ischemia (rest pain or tissue loss).
able III. Spearman correlations between serum
myloid A, high sensitive CRP, and fibrinogen with
aseline variables
Baseline
Variable
Spearman r
with SAA
(p-value)
Spearman r
with hsCRP
(p-value)
Spearman r
with Fib
(p-value)
ge .02 (.84) .07 (.54) .05 (.64)
ex .01 (.89) .09 (.41) .09 (.39)
ace .03 (.78) .01 (.89) .14 (.19)
AD .16 (.14) .12 (.26) .02 (.89)
M .38 (.0002) .3 (.004) .27 (.009)
SRD .27 (.012) .3 (.004) .18 (.09)
moker .04 (.74) .12 (.25) .03 (.81)
TN .04 (.69) .09 (.42) .12 (.27)
yperlipidemia .07 (.52) .08 (.47) .09 (.38)
tatin use .13 (.24) .03 (.75) .14 (.20)
ritical limb
ischemia
.28 (.008) .33 (.001) .35 (.0007)
AA, Serum amyloid A; hsCRP, high-sensitivity C-reactive protein; Fib,
brinogen; CAD, coronary artery disease; DM, diabetes mellitus; ESRD,
nd-stage renal disease; CLI, critical limb ischemia; HTN, hypertension.Fig 1. Scatter plots indicate preoperative levels of inflammatory
markers from 91 patients presenting for lower extremity bypass with
critical and noncritical limb ischemia (CLI). A, High-sensitivity C-
reactive protein (hsCRP) (mg/L). B, Fibrinogen (mg/dL). C, Se-
rum amyloid A (SAA) (mg/dL). Data are presented as the medianTable II. Inflammatory marker levels in the study population
N ABI CRP (mg/L
LEB-all 91 0.51 3.2 (1.4-15)
LEB/() CLI 41 0.51 6.84 (2.12-20
LEB/() CLI 50 0.49 2.02 (1.19-4.3
LEB/() event 39 0.43 6.02 (1.6-17.4
LEB/() event 52 0.59 2.74 (1.4-5.4)
ABI, Ankle-brachial index;CRP,C-reactive protein; SAA, serum amyloid A; LEB,T
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(33) were either graft-related (25) or contralateral lower
extremity events (8). Four graft events were 75% bypass
graft stenosis detected on follow-up duplex ultrasound, 11
were graft revisions, and there were 10 bypass graft occlu-
sions or amputations. Four deaths occurred, three of which
were cardiovascular-related and one was unknown.
Among patients reaching our final composite end
point, 21 (60%) of 35 were in the high-CRP risk category
(hsCRP  5 mg/L), and 18 (32%) of 56 had CRP levels
5 mg/L (P  .004, log-rank test; Fig 2). Neither SAA
(P  .44) nor fibrinogen (P  .49) was associated with
adverse events in this cohort of patients. When examining
individuals who experienced only graft-related events
(without any other cardiovascular end points), 13 (37%) of
35 were in the hsCRP-risk category, and 12 (21%) of 56
were in the lower-risk category (P  .094, log-rank test).
A multivariable Cox regression analysis was used to
evaluate factors predictive of reaching the composite end
point. Included in this model were factors with P  .1 on
univariate analysis, which were age, nonwhite race, the
presence of coronary artery disease, and critical limb isch-
emia as the reason for having lower extremity revasculariza-
tion, and a plasma hsCRP level 5 mg/L. Of these vari-
ables, only a high plasma CRP level reached significance
(P  .018, hazard ratio, 2.28; 95% confidence interval,
1.15 to 4.51) in the final model. Of note, elevated levels of
fibrinogen or SAA were not predictive in this analysis.
DISCUSSION
In this prospective evaluation of patients undergoing
lower extremity bypass surgery with autogenous vein, our
data show that higher plasma circulating levels of biochem-
ical markers of systemic inflammation—hsCRP, SAA, and
fibrinogen—are associated with increased severity of PAD
at presentation (ie, critical vs noncritical limb ischemia).
Further, in this cohort of patients, baseline hsCRP levels
independently predicted a composite end point of major
adverse postoperative events, including cardiovascular,
contralateral limb, and graft-related end points. By com-
parison, neither SAA (P  .44) nor fibrinogen (P  .49)
was significantly associated with these end points.
To our knowledge, this is the first report of a role for
hsCRP in clinical risk prediction among a cohort of patients
exclusively undergoing bypass surgery for lower extremity
ischemia. These patients, with the possible exception of
those presenting with popliteal artery aneurysms, have a
substantial burden of atherosclerosis and, arguably, are
among the most at-risk group for serious adverse cardio-
vascular, limb, and graft-related events.
Although agreement is not universal,39 CRP has been
predictive of restenosis and cardiovascular events in other
similar cohorts undergoing revascularization procedures. For
example, hsCRP levels before and after interventionhave been
associatedwith 6-month restenosis rates after femoropopliteal
angioplasty.40-42 This is consistent with the predictive ability
of preangioplasty plasma hsCRP levels for restenosis 43 as well
as death and myocardial infarction in patients undergoingpercutaneous interventions in the coronary circulation.44 In a
group of patients undergoing aortocoronary bypass grafting,
preoperative elevated levels of hsCRP (CRP3 mg/L) were
associated with an increased risk of recurrent ischemia for up
to 6 years after the procedure.45
In this study, we used a primary composite end point that
included atherosclerotic-related events (myocardial infarction,
stroke, death, and contralateral limb events) as well as vein-
graft disease, which has been considered more related to
myointimal hyperplasia. It is noteworthy that when evaluating
only the graft-related end points of stenosis, revision, and
occlusion, therewas a trend toward lowerCRP values predict-
ing freedom from adverse events (P .094).
We believe that the lack of significance in this subanalysis
is due to inadequate power. As enrollment continues to accrue
in this study (total planned, N  300), we will continue to
evaluate this relationship. Nevertheless, this should not dis-
tract from the significant, independent predictive ability of
hsCRP in relation to adverse events in this cohort. We chose
an hsCRP value of 5 mg/L as the cutoff for dichotomiza-
tion of this cohort because it represents the upper limit of
normal in our laboratory. Others have divided the hsCRP
levels into quartiles or quintiles24,46; however, our small sam-
ple size precluded us from determining any meaningful level
of significance when subdividing the population further.
Taken together, these data are a compelling implicationof
inflammation, as measured by plasma levels of hsCRP, in the
pathogenesis of restenosis after surgical intervention as well as
the development of de novo atherosclerosis-related complica-
tions. Chronic inflammation has been implicated in nearly
every step in the formation of the atherosclerotic process, as
reviewed in detail elsewhere.47,48 However, the potential role
of inflammation in the mechanisms of vein graft failure are far
more speculative. Acute injury to the vessel wall is followed by
an inflammatory response after both percutaneous revascular-
ization49 and saphenous vein bypass grafting.16,50
Whether circulating hsCRP serves as just amarker or plays
a direct biologic role in lesion development remains an area of
active investigation. Jabs et al51 demonstrated CRP staining
by immunohistochemistry in diseased human saphenous vein
grafts harvested after aortocoronary bypass surgery. The CRP
colocalized with -actin staining cells of the neointima. These
investigators concluded that the CRP expression was due to
local production within the vein graft’s wall and that the
smooth muscle cell was the likely site of origin.51 However,
the origin and biologic relevance of CRP in the vessel wall
remains an area of controversy and ongoing study.
There are limitations of this study that merit consider-
ation. With only 91 subjects and 1 year of mean follow-
up, our study lacks sufficient power to definitely evaluate
markers such as SAA and fibrinogen or to fully assess the
ability of hsCRP for accurate risk stratification. Further,
dichotomizing hsCRP at 5 mg/L may not be the best
discriminatory level for this population of patients. Indeed,
the American Heart Association considers individuals with
hsCRP values 3 mg/L to be at a high cardiovascular
risk.52 The median hsCRP value in our population was
3.2 mg/L, however, thus firmly placing our patients in the
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accrues and we have longer follow-up times will be needed
to refine the predictive abilities of hsCRP.
CONCLUSION
Webelieve these results have direct clinical relevance. The
hsCRP assay may be useful to identify a subgroup within a
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Fig 2. A, Scatter plot indicates the preoperative level of high-
sensitivity C-reactive protein (hsCRP) in 91 patients, and com-
pares those who experienced a postoperative composite end point
(myocardial infarction, cerebrovascular accident, death, contralat-
eral limb or graft-related event) with those who did not. Data are
presented as the median and interquartile range. B, Freedom from
reaching composite end point in subjects with elevated preopera-
tive hsCRP (5mg/L) compared with those with levels within the
reference range (5 mg/L) by Kaplan-Meier method (P  .018;
log-rank test). C, Freedom from graft-related events (stenosis,
revision, occlusion, or amputation of index leg) in subjects with
elevated preoperative hsCRP (5 mg/L) compared with those
with levels within the reference range (5mg/L) by Kaplan-Meier
method (P  .094; log-rank test).cohort of PAD patients that are already among the mostdisadvantaged in terms of cardiovascular morbidity and mor-
tality. This may have implications for the aggressiveness of
perioperative medical therapies, behavioral modifications,
and, potentially, for bypass graft surveillance.
Indeed, a joint conference sponsored by the Centers for
Disease Control and Prevention and the American Heart
Association recommended measurement of hsCRP in pa-
tients judged to be at intermediate risk by global risk
assessment (10% to 20% risk of coronary heart disease per
10 years), level of evidence IIa, class B.53 Although our
patients are assumed to have coronary artery disease, occult
or overt,1 this may help to identify people in whom more
intensive lipid-lowering or antiplatelet regimens may be
selected, as well as more aggressive lifestyle modification
and better compliance with existing medical therapies.
Further studies will be required to more clearly delin-
eate the relationships between systemic inflammation, con-
ventional risk factors, and the patterns of adaptive or mal-
adaptive remodeling within vein bypass grafts.
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Dr Anil Hingorani (Brooklyn, NY). While there has been a
tremendous amount of data on CRP in the cardiology literature
for the last 20 years, it really hasn’t had much clinical impact.
How is this data going to change what you do every day to your
patients undergoing lower extremity bypass procedures?
Dr Christopher D. Owens. I think that right now, we
would be hesitant to make any recommendations based on 91
patients other than pointing out that our median hsCRP level
was 3.2 mg/L, which is high risk. Five mg/L, which was ourpatients, we may be able to place these in tertiles or quartiles and
refine the predictive ability. Depending on the difference be-
tween the highest and lowest quartile, there may be an oppor-
tunity for treatment. As you know, there is beneficial data on
statins lowering CRP and improving cardiovascular outcomes.
And if that is true, CRP is a biomodulator, not just a bio-
marker, and that may have direct clinical impact in terms of
decreasing progressive atherosclerosis or decreasing vein graft
hyperplasia. So it may be an area for pharmaceutical inter-
vention.INVITED COMMENTARYStuart I. Myers, MD, Chattanooga, Tenn
As described in the article, many millions of individuals world-
wide suffer from peripheral artery disease. In the United States alone,
up to 100,000 peripheral artery reconstructions are performed each
year. Because atherosclerosis is an inflammatory disease, it is logical to
be interested in determining the role of different inflammatory mark-
ers for prognostic and potential therapy-guiding purposes.
In this particular study, the authors found that patients pre-
senting with chronic limb ischemia (CLI) had an increase in
high-sensitivity C-reactive protein (CRP), fibrinogen, and serum
amyloid levels. The most striking finding was that patients with the
highest levels of high-sensitivity CRP (0.5 mg/L) before surgery
experienced a 60% incidence ofmajor postoperative vascular events. It
is difficult to assign importance, however, because the CLI group wasAlthough the study has some design flaws, it should be of
interest to all who treat or monitor patients with CLI. The study
was also limited because it only measured the inflammatory
markers before open leg bypass.
I believe that identifying markers that predict success or
failure for treating CLI patients is even more important in
evaluating the evolving endovascular treatment techniques for
CLI. One hopes that identifying a specific marker, or a panel of
relevant markers, will contribute to predicting the success of
open and endovascular procedures for CLI as well as provide
some idea of long-term risk for major atherosclerotic vascular
events in these complex patients. This important study presents
the reader with insight into the future for monitoring and
treating CLI patients.
